The Lancet regional health. Europe · 2026
Prenatal high-dose vitamin D supplementation and offspring bone mineral content and density at age 13 years: a secondary analysis of a randomised clinical trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brustad Nicklas, Sultan Tamo, Vahman Nilo, Jensen Signe Kjeldgaard, Vinding Rebecca, Aagaard Kristina, Gørtz Peter Michael, Haarmark Christian, Bønnelykke Klaus, Chawes Bo
Аннотация
BACKGROUND: We previously demonstrated effect of maternal high-dose vitamin D supplementation on offspring bone health in preschool-age children. However, it is unknown whether this effect is long-lasting.
METHODS: We investigated the effect of 2800 (high-dose) vs. 400 (placebo + standard-dose) IU/day of gestational vitamin D supplementation on the prespecified secondary outcomes (bone mineral content and density (BMC and BMD)) at age 13 years and longitudinally (age 3, 6 and 13 years) in a double-blinded, randomized clinical trial (RCT) (NCT00856947) of 584 children in COPSAC2010. In addition, we investigated the risk of radiologically verified fractures age 0-13 years in a post hoc analysis.
FINDINGS: In 416 children (71%) with a DXA scan at age 13 years, there were no differences in a linear regression model in total body BMC (6.7 (-28.3:41.6), p = 0.71) or total body BMD (-0.003 (-0.017:0.011), p = 0.68) among children in the high-dose (n = 212) vs. standard-dose vitamin D group (n = 204). In sensitivity analyses stratified by sex, birth season or maternal pre-interventional vitamin D levels there were no differences between the intervention groups. A mixed effects model of DXA scans from age 3, 6 and 13 years combined also showed no effects and there was no effect on fracture risk until age 13 years in a Cox (time to first) or Quasi-Poisson (incidence) regression model.
INTERPRETATION: This 13-year follow-up of a prespecified secondary outcome of the COPSAC2010 vitamin D RCT did not show any lasting effect on offspring bone mineral content until age 13 years.
FUNDING: The study received funding from the Thrasher Research Fund Award and Kong Christian IX and Dronning Louises Jubilæumslegat.
METHODS: We investigated the effect of 2800 (high-dose) vs. 400 (placebo + standard-dose) IU/day of gestational vitamin D supplementation on the prespecified secondary outcomes (bone mineral content and density (BMC and BMD)) at age 13 years and longitudinally (age 3, 6 and 13 years) in a double-blinded, randomized clinical trial (RCT) (NCT00856947) of 584 children in COPSAC2010. In addition, we investigated the risk of radiologically verified fractures age 0-13 years in a post hoc analysis.
FINDINGS: In 416 children (71%) with a DXA scan at age 13 years, there were no differences in a linear regression model in total body BMC (6.7 (-28.3:41.6), p = 0.71) or total body BMD (-0.003 (-0.017:0.011), p = 0.68) among children in the high-dose (n = 212) vs. standard-dose vitamin D group (n = 204). In sensitivity analyses stratified by sex, birth season or maternal pre-interventional vitamin D levels there were no differences between the intervention groups. A mixed effects model of DXA scans from age 3, 6 and 13 years combined also showed no effects and there was no effect on fracture risk until age 13 years in a Cox (time to first) or Quasi-Poisson (incidence) regression model.
INTERPRETATION: This 13-year follow-up of a prespecified secondary outcome of the COPSAC2010 vitamin D RCT did not show any lasting effect on offspring bone mineral content until age 13 years.
FUNDING: The study received funding from the Thrasher Research Fund Award and Kong Christian IX and Dronning Louises Jubilæumslegat.